Filius Bart 4

What Happened Filius Bart, a director of ProQR Therapeutics N.V. (PRQR), acquired 150,000 common shares on 2026-06-26 at $1.54 per share, a total reported value of $231,000. The filing reports this as a purchase (Form 4 code P), which is a direct insider buy rather than a sale or award.

Key Details

• Transaction date: 2026-06-26
• Reported price and value: 150,000 shares × $1.54 = $231,000
• Transaction type: Purchase (open market or private purchase as indicated on the Form 4)
• Filing date: 2026-06-30 (filed within the SEC’s two-business-day window; not late)
• Shares owned after transaction: Not disclosed in the provided filing excerpt
• Footnotes/plan references: No 10b5-1 plan, tax withholding, or other footnotes were indicated in the provided details

Context Insider purchases can be viewed as a more informative signal than routine sales, since they represent a director deploying personal capital into the company; however, filings do not state motive. This transaction is a straightforward share purchase (not an option exercise, gift, or withholding event). For full filing details, see SEC accession 0001104659-26-079316.